Robert Bergren, MD
Ophthalmology · Monroeville, PANPI 1467407130
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $674 of the $764 with a category attached, or 88.3%. Novartis accounts for 95.7% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $731 and has fallen 97.3% since, to $19 in 2022. That places this record below the midpoint for ophthalmology clinicians in PA, where the typical reported total is $1,202.
Across 6 payments — averaging $127.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$731
- Genentech USA, Inc.$19
- Johnson & Johnson$13
Across 15 payments — averaging $12,916 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$194K
What the payments were for
- Travel & lodging$67488%
- Food & beverage$8912%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 4 | $731 |
| Genentech USA, Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BEOVU$674
How this compares
$764 in reported general payments places this provider in the 40th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 82 | $3,657 |
| Brimonidine Tartrate | 12 | $642 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 12 | $201 |
| Ketorolac Tromethamine | 16 | $190 |
| Timolol Maleate | 17 | $112 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Monroeville
- Julia HallerPhiladelphia$1.5M
- Francis MahPittsburgh$1.1M
- Brandon AyresBala Cynwyd$929K
- David AlmeidaErie$734K
- Carl RegilloPlymouth Meeting$721K
- Robert NoeckerPittsburgh$632K
- Beeran MeghparaPhiladelphia$496K
- Michael KlufasPlymouth Meeting$393K
- Jonathan MyersPhiladelphia$359K
- Mark BlecherPhiladelphia$357K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.